The 2019 JCA-Mauvernay Award, co-organized by the Japanese Cancer Association (JCA) and Swiss global biopharmaceutical company Debiopharm Group, was awarded to Doctors Ryohei Katayama from the Japanese Foundation for Cancer Research and Shinichi Yachida from Osaka University. This year marked the 15th anniversary of the recognition of outstanding research in the field of oncology in Japan. The award ceremony held on September 29th during the 78th Annual Meeting of the JCA in Kyoto, was attended by Ambassador Jean-François Paroz to show the official Swiss support and appreciation for scientific cooperation between Japan and Switzerland. Dr. Katayama researched the identification of the resistance mechanisms to molecular targeted therapies and immune checkpoint inhibitor in lung cancer, while Dr. Yachida worked on cancer clonal evolution and involvement of the microbiota in cancer development. The award was presented by Dr. Hitoshi Nakagama, President of the JCA, and Thierry Mauvernay, President and Delegate of the Board of Debiopharm. In accordance with the principles of Debiopharm, the knowledge generated by the recipients is expected to substantially drive the advancement and innovative force of the oncological field. Since 2005, the JCA and Debiopharm Group have co-organized the ‘JCA-Mauvernay Award’. This prize illustrates the curiosity that drives researchers as well as the scientific cooperation between Japan and Switzerland. It aims at recognizing outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects. For more information on the award and the event, click here.
Publish news on
Unpublish news on